7lcs: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "7lcs" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Unreleased structure''' | '''Unreleased structure''' | ||
The entry 7lcs is ON HOLD | The entry 7lcs is ON HOLD until Paper Publication | ||
Authors: Khan, M.B., Arutyunova, E., Young, H.S., Lemieux, M.J. | Authors: Khan, M.B., Arutyunova, E., Young, H.S., Lemieux, M.J. | ||
| Line 7: | Line 7: | ||
Description: Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability | Description: Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability | ||
[[Category: Unreleased Structures]] | [[Category: Unreleased Structures]] | ||
[[Category: Young, H.S]] | |||
[[Category: Khan, M.B]] | [[Category: Khan, M.B]] | ||
[[Category: | [[Category: Lemieux, M.J]] | ||
[[Category: Arutyunova, E]] | [[Category: Arutyunova, E]] | ||
Revision as of 13:21, 3 March 2021
Unreleased structure
The entry 7lcs is ON HOLD until Paper Publication
Authors: Khan, M.B., Arutyunova, E., Young, H.S., Lemieux, M.J.
Description: Improved Feline Drugs as SARS-CoV-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization for Enhanced Bioavailability
